Table 2:
Associations between continuous creatinine-corrected urinary PAH biomarker concentrations and risk of moderate or severe dysplasia.
| Model | Crude OR (95% CI)* |
p value | Adjusted OR (95% CI)ƚ |
p value |
|---|---|---|---|---|
| 1-hydroxynaphthalene | 1.63 (0.64-4.16) |
0.31 | 1.45 (0.48-4.33) |
0.51 |
| 2-hydroxynaphthalene | 3.14 (1.05-9.40) |
0.04 | 4.19 (1.01-17.47) |
0.05 |
| 2-hydroxyfluorene | 2.10 (0.71-6.19) |
0.18 | 2.21 (0.57-8.62) |
0.25 |
| 3-hydroxyfluorene | 2.59 (0.80-8.35) |
0.11 | 2.81 (0.69-11.35) |
0.15 |
| 1-hydroxyphenanthrene | 3.22 (0.85-12.20) |
0.09 | 4.96 (0.84-29.22) |
0.08 |
| 2-3-hydroxyphenanthrene | 1.77 (0.59-5.27) |
0.31 | 1.58 (0.46-5.44) |
0.19 |
| 1-hydroxypyrene | 1.82 (0.74-4.47) |
0.47 | 2.28 (0.67-7.78) |
0.19 |
OR: odds ratio per 1 natural log (~2.7 times) increase in PAH metabolite concentration
95%CI: 95% confidence interval
*
Crude models adjusted only for creatinine
ƚ
Adjusted for age, sex, ≥ primary education, family history of esophageal cancer, reported smoking status, drinking alcohol, indoor cooking, mursik drinking, and creatinine